Friday Mar 7
Friday's ETF with Unusual Volume: IBB
The iShares Nasdaq Biotechnology ETF is seeing unusually high volume in afternoon trading Friday, with over 3.1 million shares traded versus three month average volume of about 1.2 million.
Trending on the Topix Network
Wed Mar 05, 2014
Global leukemia therapeutics market: 10% CAGR between 2012-2016
One of the key factors contributing to this market growth is the significant increase in the number of cancer patients worldwide.
Ariad Pharmaceuticals Short Interest Down 2.7% in February
Ariad Pharmaceuticals was the target of a large decrease in short interest in the month of January.
Tue Mar 04, 2014
ARIAD Pharmaceuticals' CEO Presents at Cowen and Company 34th Annual...
ARIAD Pharmaceuticals Inc. Cowen and Company 34th Annual Health Care Conference Call March 4, 2014 10:40 AM ET Good morning.
Thu Feb 27, 2014
Workday Upgraded to $150 a Share; Ariad Pharmaceuticals Q4 Loss Widens
The stock was one of the biggest decliners on the . Comparable sales decreased 3.4% over the fourth quarter.
Ariad Pharmaceuticals Given "Neutral" Rating at Goldman Sachs
's stock had its "neutral" rating reiterated by analysts at Goldman Sachs in a research report issued to clients and investors on Thursday, AmericanBankingNews.com reports.
Wed Feb 26, 2014
The Motley Fool
ARIAD Pharmaceuticals, Inc. Battling Back
When Iclusig was pulled off the market, there were 640 leukemia patients on the drug.
Ariad Pharmaceuticals Upgraded to "Buy" at Maxim Group
The firm currently has a $11.00 price objective on the stock. Maxim Group's price target would suggest a potential upside of 26.87% from the company's current price.
Tue Feb 25, 2014
Wall St. Cheat Sheet
Merck Abandons Once-Promising Experimental Cancer Drug to Ariad
Merck & Co. Inc. has officially washed its hands of a once-lauded experimental cancer drug it invested in along with Ariad Pharmaceuticals Inc. Merck informed Ariad last week that it was terminating its license agreement and handing back the drug to Ariad, FierceBiotech reports.
Press release distribution, EDGAR filing, XBRL, regulatory filings
For the fourth quarter of 2013, net income attribut... )--Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central ne... )--HIMSS Conference, Booth #2515 eClinicalWorksA , a leader in ambulatory healthcare IT solutions, today announced that Central Florida's ... (more)
Ariad Pharmaceuticals' CEO Discusses Q4 2013 Results - Earnings Call Transcript
Thank you for holding for Ariad Pharmaceuticals' fourth quarter and full year 2013 financial results conference call.
ARIAD Reports 2013 Financial Results and Outlines Key Objectives for 2014
"I am extremely pleased with the commercial and R&D progress we made in 2013, especially ending the year with Iclusig commercially available to refractory Philadelphia-positive leukemia patients in the United States.
Mon Feb 24, 2014
View Press Release
Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company's business on Tuesday, March 4, at 10:40 a.m. .
Fri Feb 21, 2014
ARIAD Expands Its Board of Directors with Appointment of Alexander J. ...
ARIAD Pharmaceuticals, Inc. today announced the appointment of Alexander J. Denner, Ph.D. to a two-year term on the Company's Board of Directors, effective immediately.
Thu Feb 20, 2014
Stuart Schreiber on how H3 Biomedicine is poised for 'radical change'
Stuart L. Schreiber, director of the Center for the Science of Therapeutics at the Broad Institute of Harvard and MIT.
Wed Feb 19, 2014
An Overview Of Ariad Pharmaceuticals
Ariad Pharmaceuticals is a biotechnology company that has seen tremendous share price volatility over the past year.
ARIAD to Present at the RBC Capital Markets Healthcare Conference
ARIAD Pharmaceuticals, Inc. today announced that it will present at the RBC Capital Markets Healthcare Conference being held in New York City.
Tue Feb 18, 2014
Gainers and losers in Bay State biotechs the week of Feb. 10-14
Here are some of the companies with the biggest stock movement for the week of Feb. 10-14 among Massachusetts-based biotech, pharmaceuticals and medical device companies.
Sat Feb 15, 2014
Wall St. Cheat Sheet
3 Promising Biotechs for 2014: Ariad, Bristol-Myers, Sanomedics
Investors looking to generate substantial gains over the coming years may want to take a look at the our small-cap biotechnology companies mentioned in this article.
NASDAQ Active Stock Watch List: Ariad Pharmaceuticals Inc....
Equity Profile Report expands its NASDAQ Active Stock Watch List adding Ariad Pharmaceuticals Inc. and PDL BioPharma, Inc. .